CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to SNY

Isatuximab

Phase 3
Sanofi (SNY)

Phase 3

Development Phase

4

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jul '27
SNYPhase 2

Isatuximab Phase 2 Est. Readout

Isatuximab
Jul 2027~
CT.gov
00%
Q2 '27
SNYPhase 2

Isatuximab Phase 2 Est. Readout

Isatuximab
Q2 2027~Q
CT.gov
00%
Apr '27
SNYPhase 3

Isatuximab Phase 3 Est. Readout (GEM21menos65)

Isatuximab
Apr 2027~
CT.gov
00%
Dec '26
SNYPhase 2

Isatuximab Phase 2 Est. Readout

Isatuximab
Dec 2026~
CT.gov
00%
Development History
Nov '26
SNYPhase 2

Isatuximab Phase 2 Est. Readout (UltraFrailMM)

Isatuximab
Nov 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Plasma Cell Myeloma Refractory

View Full Landscape
Drug Information

Target Indication

Plasma Cell Myeloma Refractory

Clinical Trial

NCT04643002

Last updated: 8/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.